Angiochem, GlaxoSmithKline deal

The companies partnered to discover, develop and commercialize therapies that cross the blood brain barrier to treat neurological symptoms of lysosomal storage diseases by restoring enzyme function in the CNS. Angiochem will develop an enzyme replacement therapy using its engineered peptide compound (EPiC) technology. The biotech is responsible for development through pre-IND testing, after which GlaxoSmithKline has the option to take over further development. The EPiC peptide sequences target low-density lipoprotein-related protein 1(a-2-macroglobulin receptor; LRP1) to deliver compounds across the blood brain barrier. ...